TacticScaleWhat Vertex Pharmaceuticals Does & How It Makes Money (VRTX)
Updated October 2026 · reflects Vertex Pharmaceuticals's latest reported financials
Biotech company making medicines for cystic fibrosis and other serious diseases. Vertex makes money by selling its approved prescription medicines, led by its cystic fibrosis drugs, mostly to specialty pharmacies, distributors, wholesalers, retail pharmacies, hospitals and clinics in the US, Europe and other markets.
How Vertex Pharmaceuticals makes money
Vertex makes money by selling its approved prescription medicines, led by its cystic fibrosis drugs, mostly to specialty pharmacies, distributors, wholesalers, retail pharmacies, hospitals and clinics in the US, Europe and other markets.
What Vertex Pharmaceuticals does
Vertex Pharmaceuticals is a Boston-based biotech company, founded in 1989, that focuses on serious diseases in specialty markets. Cystic fibrosis is its core business: it sells several CFTR medicines, including TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO, which together cover CF patients from infancy through adulthood. It has added CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, and JOURNAVX for acute pain in adults. Its pipeline includes VX-522, a CFTR mRNA therapy for CF (Phase 1/2); inaxaplin for APOL1-mediated kidney disease (Phase 2); VX-264 for type 1 diabetes; VX-670 for myotonic dystrophy type 1; and VX-407 for autosomal dominant polycystic kidney disease. It also works on rare endocrine diseases and endocrine-related tumors, and has a collaboration with AbCellera to develop multispecific T-cell engagers for autoimmune diseases.
Products & services
- TRIKAFTA/KAFTRIO
- ALYFTREK
- SYMDEKO/SYMKEVI
- ORKAMBI
- KALYDECO
- CASGEVY
- JOURNAVX
What is Vertex Pharmaceuticals worth?
On an owner-earnings DCF, Vertex Pharmaceuticals's most-likely value is about $560 versus a recent price near $510 (10% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$176) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Viatris (VTRS) · Krystal Biotech (KRYS) · Vir Biotechnology (VIR) · Protagonist Therapeutics (PTGX) · Bristol-Myers Squibb (BMY)